O

OrganOx

Portable, automated organ perfusion for transplantation

Electronics Design Engineer

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor's
Oxford, UK
In PersonOn-site in Oxford; occasional travel up to 5%.
Hardware EngineeringBoard & Electronics Design

About the job

Requirements
  • Demonstrable industry experience in electronics design.
  • Strong knowledge of analogue and digital circuit design.
  • Proficiency in schematic capture and PCB layout; Altium Designer is advantageous.
  • Familiarity with electromagnetic compatibility design considerations and design-for-manufacture principles.
  • Experience with electronic testing tools such as oscilloscopes, spectrum analysers, and logic analysers.
  • Understanding of medical device standards ISO 13485, IEC 60601, and IEC 62304 is advantageous.
  • Ability to troubleshoot and solve complex design issues.
  • Effective communication skills for working within cross-functional teams.
  • A bachelor's degree in Electronics Engineering or a related discipline, or equivalent experience.
  • Ability to travel occasionally, up to 5%.
Responsibilities
  • Design and develop electronic circuits and PCB layouts, focusing on reliability, safety, and manufacturability.
  • Create schematics and PCB designs using Altium Designer.
  • Perform component selection and design calculations to meet performance specifications.
  • Conduct design verification and validation in accordance with IEC 60601 and other applicable standards.
  • Collaborate with mechanical, software, and systems engineers to integrate electronics.
  • Support prototype assembly, debugging, and troubleshooting.
  • Prepare and maintain design documentation.
  • Participate in design reviews and provide technical input for continuous product improvement.
  • Support transfer to manufacturing and assist with supplier engagement for electronics components and assemblies.
  • Adhere to the letter and spirit of OrganOx’s Code of Conduct and other company policies.
Desired Qualifications
  • Experience in regulated industries, preferably medical devices.

About the company

OrganOx develops and commercializes organ perfusion technology to keep donor organs viable for transplantation. The flagship metra device perfuses livers with oxygenated blood at body temperature, delivering nutrients and drugs to mimic normal physiology and allow viability assessment for up to 24 hours. Unlike traditional cold storage, it maintains normothermic conditions and offers direct organ assessment and longer preservation; it leases devices to transplant centers and uses disposable sets. Its goal is to increase transplantable livers and expand to other organs and applications.

Company Size

201-500

Company Stage

Acquired

Total Funding

$73.9M

Headquarters

Oxford, United Kingdom

Founded

2008

Get referred to OrganOx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Metra gained FDA approval for air transport on September 18, 2025, expanding logistics.
  • OrganOx said metra has been used in over 10,000 liver transplants by August 2026.
  • NICE endorsed routine NHS funding, which should accelerate U.K. adoption and reimbursement.

What critics are saying

  • TransMedics competes directly, and NICE excluded its OCS Liver from NHS funding.
  • OrganOx remains transplant-liver focused; failure to extend beyond metra concentrates revenue risk.
  • Post-acquisition integration into Terumo can slow execution and dilute OrganOx's entrepreneurial speed.

What makes OrganOx unique

  • OrganOx metra keeps donor livers metabolically active, enabling viability assessment before transplant.
  • Terumo completed the $1.5 billion acquisition on October 30, 2025, validating the platform.
  • NICE HTG780 named metra for routine NHS funding across England on August 20, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Wellness Program
  • Employee Discounts

Growth & Insights and Company News

6 month growth

1%

1 year growth

-1%

2 year growth

6%
TXF
Aug 24th, 2026
Terumo gets ECA support for OrganOx acquisition.

Terumo gets ECA support for OrganOx acquisition. Manufacturing & equipment Asia-Pacific, Europe JBIC signed a JPY49 billion ($307.1 million) loan with Terumo to fund part of its acquisition of UK organ preservation device company OrganOx. The financing is being provided in co-financing with private financial institutions, bringing the total co-financing amount to JPY99 billion ($620.4... Exclusive subscriber content... Not yet a subscriber? Join TXF Limited today to continue accessing content without any restrictions Or to request access to TXF Intelligence contact TXF Limited

Medical Device Network
Jan 7th, 2026
Terumo announces US launch of safety syringe

Terumo announces US launch of safety syringe. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. Terumo Medical has announced the launch of its SurTract Safety Syringe in the US, incorporating Roncadelle Operations' SafeR passive safety technology. The syringe will be distributed to clinics, emergency-care settings and hospitals across the country starting from the first quarter of this year. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. This feature withdraws the needle into the plunger after use immediately, aiming to reduce needle-stick injury risks for healthcare professionals. The system also maintains standard clinical technique while enhancing safety and ease of use. The SurTract Safety Syringe also offers a needle selection that can be customised specifically for use with SurTract Syringes, enabling physicians to choose combinations best suited to patient needs. In addition, the syringe provides a blunt needle option, which helps prevent dullness and allows for needle replacement during aspiration. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. The design contributes to less medical waste by eliminating an external plastic safety sheath. Terumo vice-president Bob Klock said: "The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections. It gives healthcare providers more - and better - treatment options for their patients, which is our ultimate goal." Roncadelle operations chief business development officer Dr Fred Metzmann said: "Terumo has significantly advanced injection safety with the integration of our SafeR technology. Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals." The company's SafeR product line includes needle-guard systems and passive safety syringes designed for safe injection and protection in clinical environments. In October 2025, Terumo completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.

MD+DI
Aug 28th, 2025
Medtech in a Minute: A Verily Big Decision & More

Terumo has agreed to acquire OrganOx for about $1.5B. OrganOx specializes in advanced Normothermic Machine Perfusion devices for organ preservation.

UK Tech News
Aug 26th, 2025
Japan's Terumo acquires Oxford health tech in $1.5bn deal

OrganOx, a University of Oxford spinout that has developed an automated device to preserve organs in transit, has been acquired by Tokyo-based medical manufacturer Terumo for $1.5bn (£1.1bn).

TechStartups
Aug 25th, 2025
Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history

From lab to $1.5B exit: Oxford spinout OrganOx acquired by Terumo.